8-K: Seer Inc. Reports Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Outlook

Seer Inc. announces its Q4 and full year 2024 financial results, highlighting revenue, instrument shipments, and a positive outlook for 2025.

Summary

• Seer Inc. reported a revenue of $4.0 million for Q4 2024 and $14.2 million for the full year.
• This represents a 10% decrease in Q4 revenue and a 15% decrease in full-year revenue compared to the previous year.
• The company shipped 10 instruments in 2024, bringing the cumulative total to 72.
• Seer launched a new product application for cell lysis proteomics.
• The company repurchased 6.5 million shares at an average cost of $1.82 per share, reducing shares outstanding by approximately 10%.
• Seer ended the year with approximately $300 million in cash, cash equivalents, and investments.
• The company expects full-year 2025 revenue to be in the range of $17 million to $18 million, representing a 24% growth at the midpoint.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue decreased year-over-year, the company is projecting significant growth in 2025 and has a strong cash position. The share repurchase program is also a positive sign.

Positives

• Seer launched a new product application for the Proteograph XT workflow.
• The company repurchased shares, reducing the number of outstanding shares by approximately 10%.
• Seer maintains a strong cash position with approximately $300 million in cash, cash equivalents, and investments.
• The company anticipates revenue growth of 24% in 2025, with revenue expected to be in the range of $17 million to $18 million.

Negatives

• Q4 2024 revenue decreased by 10% compared to the previous year.
• Full year 2024 revenue decreased by 15% compared to the previous year.
• The decrease in revenue is primarily attributed to lower product sales and the absence of grant revenue.

Risks

• The company acknowledges a challenging macroeconomic environment.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Seer expects full year 2025 revenue to be in the range of $17 million to $18 million, representing growth of 24% at the midpoint over full year 2024.

Management Comments

• Omid Farokhzad, Chair and CEO of Seer, stated that customers have made important progress in validating the value of deep, unbiased proteomics.
• He expressed confidence in the company's platform, value proposition, and the immense opportunity ahead.

Industry Context

The announcement highlights Seer's efforts to expand its presence in the proteomics market through product innovation and strategic partnerships, such as the one with Thermo Fisher Scientific. The company is focused on enabling deep, unbiased proteomic analysis at scale, which is a growing trend in life sciences research.

Comparison to Industry Standards

• It's difficult to directly compare Seer's results to industry standards without knowing the specific growth rates and financial metrics of its direct competitors in the proteomics market.
• Companies like Quanterix, SomaLogic, and Olink are also focused on proteomics but employ different technologies and business models.
• Seer's focus on unbiased, deep proteomic analysis at scale differentiates it from some competitors that focus on targeted protein measurements.
• The 24% revenue growth projected for 2025 would be a positive sign if achieved, indicating strong market adoption of its Proteograph platform.

Related Party Transactions

• Product revenue for the fourth quarter of 2024 included $36 thousand of related party revenue.
• Service revenue for the fourth quarter of 2024 included $353 thousand of related party revenue.
• Product revenue for the full year 2024 included $1.5 million of related party revenue.
• Service revenue for the full year 2024 included $828 thousand of related party revenue.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue for 2024 but encouraged by the projected growth in 2025 and the share repurchase program.
• Employees may be affected by the company's financial performance, but the positive outlook for 2025 could provide reassurance.
• Customers benefit from the new product applications and advancements in proteomics research enabled by Seer's technology.

Key Dates